High Expression of Class III Β-Tubulin Predicts Good Response to Neoadjuvant Taxane and Doxorubicin/Cyclophosphamide-Based Chemotherapy in Estrogen Receptor–Negative Breast Cancer
Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2012.11.003
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2013
Authors
Publisher
Elsevier BV